Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

171.73 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
Via Benzinga
Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever
There is something for everybody in America's $4.5 trillion healthcare market. 
Via The Motley Fool
AbbVie Stock Post Humira is Still an Attractive Stock to Hold
AbbVie's strategic diversification and strong financial position make it possible to sustain growth despite the perceived “Humira cliff.” 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
AbbVie Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Dividend Stocks You Can Safely Hold Through a Recession
These stocks can help you sleep peacefully at night, even in bad times. 
Via The Motley Fool
AbbVie Unusual Options Activity For August 26
Via Benzinga
Key Takeaways From AbbVie Analyst Ratings
Via Benzinga
Unpacking the Latest Options Trading Trends in AbbVie
Via Benzinga
2 High-Yield Dividend Stocks to Buy in September and Hold for a Decade or Longer
A drugmaker and a telecom business have what it takes to safely boost your passive income stream. 
Via The Motley Fool
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
2 Monster Stocks You Can Buy Right Now Before They Surge Even Higher
These businesses can stand the test of time in a diversified portfolio. 
Via The Motley Fool
3 Rock-Solid Pharma Stocks to Buy Now and Hold Forever
These three have secure core businesses, plus multiple paths to grow. 
Via The Motley Fool
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
Via Benzinga
2 Incredibly Cheap Healthcare Stocks to Buy Now
Top healthcare stocks are a great addition to any portfolio. 
Via The Motley Fool
Biotech And Life Science Sector Update Summer Of 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
There are three operative words with these dividend stocks: buy and hold. 
Via The Motley Fool
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose. 
Via Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial. 
Via Investor's Business Daily
3 Best Growth Stocks to Own for the Next 10 Years
When in doubt, zoom out; these three growth stocks have a history of strong performance that is likely to continue for the next 10 years 
Via MarketBeat
Topics Economy
Exposures Economy
Prediction: Eli Lilly's Latest Move Will Threaten AbbVie Stock
It'll be a while before there's any impact, but it could be a big deal. 
Via The Motley Fool
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports. 
Via Benzinga
Donald Trump Owns These 21 Dividend Kings. Should You?
Some of Trump's Dividend Kings deserve a crown more than others. 
Via The Motley Fool
Topics Government
Exposures Political
3 Unstoppable Dividend Stocks to Buy Right Now
These stocks are the A-team for income investors. 
Via The Motley Fool
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,... 
Via Benzinga
How To Build A Dividend Growth Portfolio In An Overpriced Market
The stock market as measured by the S&P is currently at an all-time high which makes it very challenging to try to build a quality dividend growth portfolio. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Biotech Bull Market: 3 Ways To Play It
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS